The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study
Journal of Current Hematology & Oncology Research · 08.08.2026 · 4 (3) · 86-92
DOI: 10.51271/jchor-0088 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 08.08.2026. Verfasst von Ali Aytaç und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
The Advanced Lung Cancer Inflammation Index (ALI)—calculated from body mass index (BMI), serum albumin, and neutrophil-to-lymphocyte ratio (NLR)—is an accessible composite biomarker of systemic inflammation and nutritional status. Its prognostic value in second-line immune checkpoint inhibitor (ICI) therapy in an ICI-naive population remains undefined.
Methods
This multicenter retrospective cohort study included 249 metastatic non-small cell lung cancer (NSCLC) patients treated with second-line single-agent nivolumab without prior immunotherapy exposure. ALI was categorized using a receiver operating characteristic (ROC)-derived cut-off of 27.27. Treatment response was assessed by RECIST 1.1. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression models.
Results
High baseline ALI (>=27.27) was associated with significantly longer median PFS (10.05 vs. 6.01 months; p=0.012) and OS (13.89 vs. 6.27 months; p
Zitieren
APA
Aytaç, A., Demir, B., Canaslan, K., Ellez, H. İ., & Camadan, Y. A. (2026). The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study. Journal of Current Hematology & Oncology Research, 4(3), 86-92. https://doi.org/10.51271/jchor-0088
Vancouver
Aytaç A, Demir B, Canaslan K, Ellez Hİ, Camadan YA. The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study. Journal of Current Hematology & Oncology Research. 2026;4(3):86-92. doi:10.51271/jchor-0088
BibTeX
@article{Ayta2026,
author = {Aytaç, Ali and Demir, Bilgin and Canaslan, Kübra and Ellez, Halil İbrahim and Camadan, Yasemin Aydınalp},
title = {The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study},
journal = {Journal of Current Hematology & Oncology Research},
year = {2026},
volume = {4},
number = {3},
pages = {86--92},
doi = {10.51271/jchor-0088}
}
EUVIMED